וקטור פלוס 16012.5 ישראל - עברית - Ministry of Health

וקטור פלוס 16012.5

unipharm ltd, israel - hydrochlorothiazide; valsartan - טבליה - valsartan 160 mg; hydrochlorothiazide 12.5 mg - valsartan - valsartan - for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

קסלודה 150 מ"ג ישראל - עברית - Ministry of Health

קסלודה 150 מ"ג

roche pharmaceuticals (israel) ltd - capecitabine 150 mg - film coated tablets - capecitabine - adjuvant colon cancer: xeloda is indicated for the adjuvant treatment of patients following surgery of stage iii (dukesע stage c) colon cancer. colorectal cancer: xeloda is indicated for the treatment of patients with advanced or metastatic colorectal cancer advanced gastric cancer: xeloda is indicated for first line treatment of advanced gastric cancer in combination with chemotherapy breast cancer combination therapy: xeloda in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. breast cancer monotherapy: xeloda is also indicated for the treatment of advanced or metastatic breast cancer after failure of standard therapy including a taxane unless therapy with a taxane is clinically contraindicated.

קסלודה 500 מ"ג ישראל - עברית - Ministry of Health

קסלודה 500 מ"ג

roche pharmaceuticals (israel) ltd - capecitabine 500 mg - film coated tablets - capecitabine - adjuvant colon cancer: xeloda is indicated for the adjuvant treatment of patients following surgery of stage iii (dukesע stage c) colon cancer. colorectal cancer: xeloda is indicated for the treatment of patients with advanced or metastatic colorectal cancer advanced gastric cancer: xeloda is indicated for first line treatment of advanced gastric cancer in combination with chemotherapy breast cancer combination therapy: xeloda in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. breast cancer monotherapy: xeloda is also indicated for the treatment of advanced or metastatic breast cancer after failure of standard therapy including a taxane unless therapy with a taxane is clinically contraindicated.

טקסוטר ישראל - עברית - Ministry of Health

טקסוטר

sanofi - aventis israel ltd - docetaxel as trihydrate 20 mg / 1 ml - concentrate for solution for infusion - docetaxel - breast cancer: taxotere (docetaxel) in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. taxotere (docetaxel) in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. taxotere(docetaxel) monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent. taxotere (docetaxel) in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress her2 and who previously have not received chemotherapy for metastatic disease. taxotere (docetaxel) in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy.

דוסטאקסל הוספירה 10 מגמל ישראל - עברית - Ministry of Health

דוסטאקסל הוספירה 10 מגמל

pfizer pfe pharmaceuticals israel ltd - docetaxel - תמיסה לאינפוזיה - docetaxel 10 mg / 1 ml - docetaxel - docetaxel - breast cancer: docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. docetaxel in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. docetaxel monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent. docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress her2 and who previously have not received chemotherapy for metastatic disease. docetaxel in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracyclin

פגסיס 135 מק"ג/0.5 מ"ל ישראל - עברית - Ministry of Health

פגסיס 135 מק"ג/0.5 מ"ל

roche pharmaceuticals (israel) ltd - peginterferon alfa 2a 135 mcg / 0.5 ml - solution for injection - peginterferon alfa-2a - chronic hepatitis b: pegasys is indicated for the treatment of both hbeag- positive and hbeag -negative chronic hepatitis b in non-cirrhotic and cirrhotic adult patients with compensated liver disease and evidence of viral replication and liver inflammation.chronic hepatitis c: pegasys is indicated for the treatment of chronic hepatitis c in adult patients who are positive for serum hcv-rna including patients with compensated cirrhosis and/or co-infected with clinically stable hiv. the optimal way to use pegasys in patients with chronic hepatitis c is in combination with ribavirin. the combination of pegasys and ribavirin is indicated in naive patients and patients who have failed previous treatment with interferon alpha (pegylated or non-pegylated ) alone or in combination therapy with ribavirin. monotherapy is indicated mainly in case of intolerance or contraindication to ribavirin.

פגסיס 180 מק"ג/0.5 מ"ל ישראל - עברית - Ministry of Health

פגסיס 180 מק"ג/0.5 מ"ל

roche pharmaceuticals (israel) ltd - peginterferon alfa 2a 180 mcg / 0.5 ml - solution for injection - peginterferon alfa-2a - chronic hepatitis b: pegasys is indicated for the treatment of both hbeag- positive and hbeag -negative chronic hepatitis b in non-cirrhotic and cirrhotic adult patients with compensated liver disease and evidence of viral replication and liver inflammation.chronic hepatitis c: pegasys is indicated for the treatment of chronic hepatitis c in adult patients who are positive for serum hcv-rna including patients with compensated cirrhosis and/or co-infected with clinically stable hiv. the optimal way to use pegasys in patients with chronic hepatitis c is in combination with ribavirin. the combination of pegasys and ribavirin is indicated in naive patients and patients who have failed previous treatment with interferon alpha (pegylated or non-pegylated ) alone or in combination therapy with ribavirin. monotherapy is indicated mainly in case of intolerance or contraindication to ribavirin.

יומירה 40 מ"ג ישראל - עברית - Ministry of Health

יומירה 40 מ"ג

abbvie biopharmaceuticals ltd, israel - adalimumab 40 mg / 0.8 ml - solution for injection - pen - adalimumab - * rheumatoid arthritis: humira in combination with methotrexate is indicated for: - the treatment of moderate to severe active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. humira has been shown to reduce the rate of progression of joint damage as measured by x-ray adn to impove physical function when given in combination with methotrexate. * crohn's disease : humira is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohn's disease who have had an inadequate response to conventional therapy.humira is indicated for reducing signs and symptoms and inducing clinical r

למיקטל טבליות מסיסות/לעיסות 50 מ"ג ישראל - עברית - Ministry of Health

למיקטל טבליות מסיסות/לעיסות 50 מ"ג

glaxo smith kline (israel) ltd - lamotrigine 50 mg - dispersible/chewable tablets - lamotrigine - epilepsy: monotherapy in adults and children over 12 years of age: 1. simple partial seizures. 2. complex partial seizures. 3. generalised tonic clonic secondarily seizures. 4. primary generalised tonic clonic seizures. add-on therapy in adults and children over 2 years of age: 1. simple partial seizures. 2. complex partial seizures. 3. secondarily generalised tonic clonic seizures. adults (18 years of age and over) lamotrigine is indicated for the prevention of mood episodes in patients with bipolar disorder predominantly by preventing depressive episodes.

למיקטל טבליות מסיסות/לעיסות 200 מ"ג ישראל - עברית - Ministry of Health

למיקטל טבליות מסיסות/לעיסות 200 מ"ג

glaxo smith kline (israel) ltd - lamotrigine 200 mg - dispersible/chewable tablets - lamotrigine - epilepsy: monotherapy in adults and children over 12 years of age: 1. simple partial seizures. 2. complex partial seizures. 3. generalised tonic clonic secondarily seizures. 4. primary generalised tonic clonic secondarily seizures. add-on therapy in adults and children over 2 years of age: 1. simple partial seizures. 2. complex partial seizures. 3. secondarily generalised tonic clonic seizures. adults (18 years of age and over) lamotrigine is indicated for the prevention of mood episodes in patients with bipolar disorder predominantly by preventing depressive episodes.